US Digital Twins in Healthcare Market Report Scope & Overview:

The US Digital Twins in Healthcare Market was valued at USD 0.87 Billion in 2025 and is projected to reach USD 27.34 Billion by 2035, registering a CAGR of 41.34% from 2026 to 2035.

The US Digital Twins in Healthcare Market continues to lead global adoption as a dense concentration of leading health systems, academic medical centers and technology vendors pilot early-stage digital-twin applications across imaging, therapy planning and hospital operations. Deep cloud-computing infrastructure and AI research talent concentrated across major U.S. technology and healthcare hubs continue giving domestic health systems an early-mover advantage in building internal digital-twin expertise.

Growing venture and strategic investment in precision-medicine and AI-enabled care platforms continues reinforcing the United States' position as the largest national market tracked in this report. Hospital networks are increasingly partnering with cloud-computing providers to deploy patient-specific and operational digital twins at scale, and expanding FDA regulatory clarity around software-as-a-medical-device frameworks is gradually easing commercialization pathways for new digital-twin applications nationwide.

⮞In 2026, Microsoft continued expanding its Azure healthcare cloud capabilities to support interoperable health data management and AI-driven clinical workflows; however, the specific nationwide expansion and new physiological-modeling features described remain unverified.

Global Digital Twins in Healthcare Market Size

The Global Digital Twins in Healthcare Market had a value of USD 2.22 billion in 2025 and is forecasted to reach USD 69.67 billion in 2035 at a CAGR of 41.17% from 2026 to 2035. The growth will be driven by increasing use of AI-based personalized medicine, predictive healthcare modeling, and virtual simulation that improves clinical decision making and increases efficiency.

North America Digital Twins in Healthcare Market Size

The North America Digital Twins in Healthcare Market was valued at USD 0.94 Billion in 2025 and is projected to reach USD 29.77 Billion by 2035, registering a CAGR of 41.27% from 2026 to 2035, driven by advanced healthcare IT infrastructure, rising investments in AI-enabled precision medicine, and growing adoption of patient-specific digital twins across hospitals and healthcare technology providers.

By Type, Process & System Digital Twin Dominates the US Digital Twins in Healthcare Market, Product Digital Twin Grows Fastest

Process & System Digital Twin solutions dominated U.S. demand, reflecting hospitals' early focus on operational efficiency gains that deliver measurable cost savings without requiring regulatory clearance for patient-facing clinical use. Large domestic hospital networks continue favoring process-level twins as the natural entry point for building internal digital-twin expertise before expanding into patient-specific clinical applications. Established health-information-technology budgets nationwide further reinforce this segment's dominant revenue contribution relative to newer product-level applications still gaining regulatory traction across the country. Growing availability of off-the-shelf operational-twin software is further lowering adoption barriers for smaller, resource-constrained hospitals across the country.

Product Digital Twin solution segment is anticipated to grow significantly, owing to an increase in the use of virtual models by medical device manufacturers in the U.S. in both the development and monitoring phases of their medical devices. The increased interest shown by the FDA regarding the use of digital twins for validation purposes adds to the rapid growth of this segment, especially with regard to implants and surgical devices, where physical tests can prove to be expensive. Collaboration between the domestic medical device manufacturers and simulation software providers is hastening the deployment of product-level twins throughout the country.

⮞In August 2025, OSF HealthCare announced that its 4D Heart technology was using AI-assisted analysis to create patient-specific, moving three-dimensional heart models, supporting surgical planning and illustrating the clinical potential of product-level digital twins.

By Application, Personalized Medicine Dominates the US Digital Twins in Healthcare Market, Drug Discovery Grows Fastest

Personalized Medicine applications dominated U.S. demand as health systems increasingly deploy patient-specific digital twins to model individualized treatment responses across oncology, cardiology and chronic-disease management. Growing clinician confidence in simulation-informed treatment planning, reinforced by outcomes data accumulating at leading academic medical centers, continues strengthening this application's position as the largest domestic revenue contributor. Expanding integration between electronic health records and digital-twin platforms is further embedding personalized-medicine applications into routine clinical workflows nationwide. Growing payer interest in outcomes-based reimbursement is additionally reinforcing demand for simulation-informed care across the country's leading health systems.

Drug Discovery applications are forecast to grow fastest as U.S. pharmaceutical developers increasingly use patient-population digital twins to simulate trial outcomes and reduce late-stage clinical failure rates. Growing adoption of virtual control arms and in-silico trial design is reinforcing this above-average growth trajectory across both large originator companies and smaller biotech sponsors concentrated in major domestic biotech hubs. Expanding collaboration between drug developers and specialized simulation-software vendors is further accelerating demand for drug-discovery-focused capacity nationwide. Rising FDA openness to simulation-supported submissions is further reinforcing this application's above-average growth outlook.

⮞In October 2026, Stanford Medicine researchers received up to USD 41.4 million through ARPA-H's CIRCLE program to develop an AI-based digital twin of patients' immune responses, aiming to predict intensive-care outcomes and identify potentially effective immunotherapies for critically ill patients.

By End-use, Hospitals and Clinics Dominate the US Digital Twins in Healthcare Market, Clinical Research Organizations Grow Fastest

Hospitals and Clinics accounted for the largest end-use share in the United States, reflecting their position as both the primary adopters and largest potential beneficiaries of operational and patient-specific digital-twin applications. Established capital budgets for health-information-technology investment across large domestic hospital networks continue reinforcing this segment's dominant revenue contribution. Multi-facility hospital networks nationwide are particularly well positioned to justify digital-twin investment given the scale economies available across shared operational and clinical modeling platforms. Growing administrator familiarity with simulation-based planning tools is further reinforcing this segment's adoption advantage. Several large hospital systems have further consolidated vendor panels around strategically important technology partners.

Clinical Research Organizations are forecast to grow fastest as U.S. CROs increasingly offer digital-twin-enabled trial design services to differentiate themselves in a competitive outsourced-research market. Growing sponsor demand for faster, lower-cost trial execution is reinforcing this above-average growth trajectory, particularly for CROs serving smaller biotech companies without in-house simulation expertise. Expanding partnerships between domestic CROs and digital-twin technology vendors are further widening the range of trial designs incorporating simulation-based modeling nationwide across multiple therapeutic areas. Growing numbers of first-time sponsors are further reinforcing this segment's growth outlook.

⮞In February 2026, Unlearn announced that it would apply AI-generated digital twins to VectorY Therapeutics' PIONEER-ALS study, supporting clinical-trial analysis through participant-specific outcome forecasts and demonstrating commercial use of simulation technology in outsourced drug-development programs.

Regional Analysis

West US Digital Twins in Healthcare Market Insights

The West dominated the US Digital Twins in Healthcare Market with the largest sub-regional revenue share of approximately 34.72% in 2025, supported by California's dense concentration of technology companies, biotech firms and leading academic medical centers. Proximity to major AI research institutions and venture-capital funding continues reinforcing the West's leadership position relative to other U.S. sub-regions, particularly for AI-enabled personalized-medicine applications. A deep regional base of software engineering talent further supports rapid platform iteration and deployment across major health systems.

California accounted for the largest share of West Coast revenue, anchored by a dense concentration of health-technology companies and research institutions, while Washington contributed additional demand through specialty digital-health adoption. Continued venture-capital investment in digital-health technology should keep the West's leadership position intact through the forecast period, reinforced by decades of accumulated AI and simulation-software expertise across multiple major technology companies headquartered in the region. Expanding university-affiliated incubator programs are further feeding a steady pipeline of new ventures across the region.

⮞In September 2026, Stanford Medicine researchers received up to USD 41.4 million in ARPA-H funding to develop an AI-based digital twin of patients' immune responses, targeting better outcome prediction and individualized treatment decisions in intensive-care settings.

Northeast US Digital Twins in Healthcare Market Insights

The Northeast held a meaningful share of U.S. revenue, supported by New Jersey's and New York's dense concentration of medical-device manufacturers, pharmaceutical headquarters and leading academic medical centers. Proximity to major health-system decision-makers and regulatory affairs talent continues reinforcing the Northeast's position as a significant contributor to domestic digital-twin adoption, particularly for drug-discovery and device-validation applications. A deep regional base of contract-research and clinical-trial infrastructure further supports faster platform validation timelines across the Northeast corridor and its surrounding metropolitan health systems.

New Jersey accounted for a substantial share of Northeast revenue, anchored by multiple medical-device and pharmaceutical company headquarters, while Pennsylvania and New York contributed additional demand through hospital-network and research-institute adoption. Continued originator investment in digital-twin-enabled drug development should keep the Northeast's position intact through the forecast period, reinforced by decades of accumulated regulatory and clinical-research expertise across multiple major originator companies headquartered in the region and their established supplier networks spanning multiple manufacturing, research and distribution sites nationwide.

⮞In September 2026, Rutgers University and RWJBarnabas Health launched an innovation hub powered by Amazon Web Services, combining clinical expertise, cloud computing and AI to advance healthcare innovation and technology-driven patient care across New Jersey.

Midwest and South US Digital Twins in Healthcare Market Insights

The Midwest held a meaningful share of U.S. revenue, supported by Illinois's established healthcare-technology base and proximity to major hospital-network operations. Indiana and Ohio contributed additional demand through specialty health-technology adoption serving both regional hospital systems and research institutions, reinforced by a deep regional base of engineering talent and lower operating costs than coastal technology hubs. Established logistics and data-center infrastructure across the Midwest further supports efficient cloud-based platform deployment across multiple hospital networks.

The South is expected to grow at the fastest CAGR nationally, led by North Carolina's expanding biotechnology and digital-health cluster centered around the Research Triangle, with Texas also beginning to attract new health-technology investment. Continued state-level incentive programs across both regions are expected to support further adoption growth through the forecast period, as more health systems evaluate lower-cost domestic alternatives to coastal technology hubs for new digital-twin pilot programs. Growing availability of skilled technology talent near Research Triangle-area universities is further reinforcing the South's appeal to new investors.

⮞In January 2026, the University of Chicago's medical, data-science and information-technology teams highlighted their ADAMS Center collaboration to centralize healthcare data and create synthetic datasets, helping researchers analyze clinical information while protecting patient privacy and strengthening infrastructure for computational healthcare modeling.

⮞In June 2026, North Carolina's health and information-technology departments announced three digital-health programs under the state's Rural Health Transformation Program, advancing digital infrastructure and technology adoption among rural providers and expanding the potential environment for data-driven healthcare modeling.

Market Dynamics

Growth Drivers: AI-Enabled Care Models and Precision-Medicine Investment

The U.S. industry is driven by growing hospital investment in operational efficiency technology, expanding precision-medicine and drug-discovery applications for patient-specific simulation, and rising clinician confidence in AI-assisted decision support nationwide. As health systems prioritize both cost containment and improved clinical outcomes, demand for domestic digital-twin platform capacity continues rising across the country.

Growing cloud-computing capacity investment, reinforced by Microsoft's and Oracle's continued platform-expansion activity, is reinforcing this driver by giving health systems and biotech companies flexible access to simulation infrastructure. Expanding collaboration between technology vendors and hospital networks is further widening the addressable customer base able to justify early digital-twin platform investment nationwide.

⮞In September 2026, Stanford Medicine reported that its research team had secured ARPA-H support to develop digital twins of patients' immune responses, advancing research into individualized treatment selection and outcome prediction for critically ill patients.

Restraints: High Implementation Costs and Data-Integration Complexity

High implementation and integration costs continue restraining faster capacity expansion across the United States, as building accurate digital-twin models requires substantial investment in sensors, data infrastructure and specialized modeling expertise before measurable returns materialize. Many smaller U.S. hospitals continue lacking the capital and technical staff needed to deploy digital-twin platforms at meaningful scale.

Data-integration complexity across fragmented electronic health record systems also complicates digital-twin deployment decisions for health systems operating multiple legacy platforms nationwide. Because validating a new digital-twin application against real-world clinical outcomes can take several years, some hospitals continue favoring narrower, lower-risk operational pilots over broader patient-specific clinical deployment.

Opportunities: Drug-Discovery Expansion and Biotech CDMO-Style Partnerships

Growing pharmaceutical sponsor interest in drug-discovery and clinical-trial simulation applications represents a significant opportunity across the United States, as technology vendors able to demonstrate measurable reductions in development timelines and trial costs capture meaningful share. Manufacturers positioned early in domestic simulation-platform expansion stand to benefit as digital-health modernization continues through the forecast period.

Expansion of partnerships between hospital systems and specialized digital-twin technology vendors offers a second opportunity for domestic manufacturers able to offer flexible, scalable simulation capacity. Continued collaboration between health systems and technology vendors is expected to further accelerate this opportunity through the remainder of the forecast period.

⮞In January 2026, Unlearn introduced TrialPioneer, an AI-powered workspace designed to help clinical-development teams strengthen early-stage trial planning by evaluating study designs, eligibility criteria, endpoints and sample-size assumptions before protocol finalization.

US Digital Twins in Healthcare Companies are:

• Microsoft Corporation

• IBM Corporation

• Oracle Corporation

• NVIDIA Corporation

• Hewlett Packard Enterprise Company

• GE Healthcare Technologies Inc.

• ANSYS, Inc.

• Altair Engineering Inc.

• Unlearn.AI, Inc.

• Twin Health, Inc.

• Q Bio, Inc.

• Dassault Systèmes SE

• Siemens Healthineers AG

• Philips Healthcare

• Atos SE

• Virtonomy GmbH

• PrediSurge

• InSilicoTrials Technologies, Inc.

• Faststream Technologies

• Cortex Labs

US Digital Twins in Healthcare Market Report Scope: